Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned an average rating of “Moderate Buy” from the nineteen brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, thirteen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $38.4706.

DYN has been the topic of a number of research analyst reports. Oppenheimer upgraded shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $11.00 to $40.00 in a report on Wednesday, December 10th. Cowen reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Evercore ISI reduced their price objective on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Stifel Nicolaus increased their price objective on Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, December 11th.

Dyne Therapeutics Price Performance

Shares of DYN opened at $19.85 on Monday. The stock has a 50 day simple moving average of $19.70 and a 200 day simple moving average of $14.52. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $26.22. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47. The firm has a market capitalization of $2.83 billion, a PE ratio of -5.42 and a beta of 1.30.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. Sell-side analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DYN. Vanguard Group Inc. lifted its position in shares of Dyne Therapeutics by 27.6% in the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. RA Capital Management L.P. grew its position in Dyne Therapeutics by 52.2% in the first quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company’s stock valued at $101,613,000 after purchasing an additional 3,333,248 shares in the last quarter. Atlas Venture Life Science Advisors LLC increased its stake in Dyne Therapeutics by 13.9% in the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company’s stock valued at $95,505,000 after buying an additional 1,111,111 shares during the last quarter. TCG Crossover Management LLC lifted its position in Dyne Therapeutics by 22.5% during the 3rd quarter. TCG Crossover Management LLC now owns 4,615,144 shares of the company’s stock worth $58,382,000 after buying an additional 848,484 shares in the last quarter. Finally, Braidwell LP lifted its position in Dyne Therapeutics by 431.6% during the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company’s stock worth $37,879,000 after buying an additional 2,940,162 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.